315 related articles for article (PubMed ID: 34530558)
21. [Clinical analysis of 156 patients with gastrointestinal stromal tumors receiving imatinib therapy].
Zhang L; Cai M; Deng J; Wang X; Wang B; Liu N; Pan Y; Zhang R; Cui Q; Liang H
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr; 17(4):331-4. PubMed ID: 24760639
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of gastric gastrointestinal stromal tumors in Shandong Province: a midterm report of multicenter GISSG1201 study].
Hou Q; Luo W; Li L; Dai Y; Jiang L; Wang A; Chu X; Li Y; Yang D; Lu C; Yao L; Cui G; Lin H; Chen G; Cui Q; Zhang H; Lun Z; Xia L; Su Y; Han G; Hui X; Wei Z; Sun Z; Guo H; Zhou Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1025-1030. PubMed ID: 28900994
[TBL] [Abstract][Full Text] [Related]
23. [Clinicopathological analysis of 61 patients with rectal gastrointestinal stromal tumors].
Wu X; Jiang W; Zhang R; Ding P; Chen G; Lu Z; Li L; Fang Y; Wang F; Kong L; Lin J; Pan Z; Wan D
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr; 17(4):335-9. PubMed ID: 24760640
[TBL] [Abstract][Full Text] [Related]
24. [Treatment and prognosis of 108 patients with high-risk gastrointestinal stromal tumor].
Lei C; Liu L; Wang Q; Wang H
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1300-1304. PubMed ID: 27928804
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
Li J; Dang YZ; Gao J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):216-20. PubMed ID: 23536338
[TBL] [Abstract][Full Text] [Related]
26. [Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients].
Yang LX; Wang M; Xu RH; Tu L; Zhuang C; Zhao WY; Ma XL; Li M; Zhang J; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):841-847. PubMed ID: 31550823
[No Abstract] [Full Text] [Related]
27. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
Joensuu H; Eriksson M; Sundby Hall K; Reichardt A; Hermes B; Schütte J; Cameron S; Hohenberger P; Jost PJ; Al-Batran SE; Lindner LH; Bauer S; Wardelmann E; Nilsson B; Kallio R; Jaakkola P; Junnila J; Alvegård T; Reichardt P
JAMA Oncol; 2020 Aug; 6(8):1241-1246. PubMed ID: 32469385
[TBL] [Abstract][Full Text] [Related]
28. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
Shen L; Jin ML
Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
[TBL] [Abstract][Full Text] [Related]
29. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.
Casali PG; Le Cesne A; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Adenis A; Hartmann JT; Duffaud F; Goldstein D; Broto JM; Gronchi A; Dei Tos AP; Marréaud S; van der Graaf WT; Zalcberg JR; Litière S; Blay JY
J Clin Oncol; 2015 Dec; 33(36):4276-83. PubMed ID: 26573069
[TBL] [Abstract][Full Text] [Related]
30. Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).
Tang S; Yin Y; Shen C; Chen J; Yin X; Zhang B; Yao Y; Yang J; Chen Z
World J Surg Oncol; 2017 Apr; 15(1):79. PubMed ID: 28399894
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of clinical features and prognostic factors on reoperation patients with postoperative recurrence or metastasis of gastrointestinal stromal tumor].
Wang L; Xu W; Yao X; Yan C; Li C; Zhu Z; Liu W; Yan M
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1274-1279. PubMed ID: 30506539
[TBL] [Abstract][Full Text] [Related]
32. [Clinical characteristics and prognosis analysis of 119 cases with giant gastrointestinal stromal tumor].
Zhang P; Zeng X; Gao J; Liu W; Shuai X; Liu K; Liu X; Cai M; Cai K; Wang G; Tao K
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1290-1295. PubMed ID: 27928802
[TBL] [Abstract][Full Text] [Related]
33. [A Chinese multi-center study on the significance of monitoring imatinib plasma concentration in patients with gastrointestinal stromal tumor before and after administration].
Xu H; Ma L; Xu W; Guan W; Wang B; Li G; Miao Y; Li L; Chen H; Yu J; Wang Y; Sun L; Yang L; Zhang D; Li F; Zhi X; Wang J; Xu J; Xu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1271-1276. PubMed ID: 27928798
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant imatinib treatment in gastrointestinal stromal tumor: which risk stratification criteria and for how long? A case report.
Blay JY; Levard A
Anticancer Drugs; 2016 Jan; 27(1):71-5. PubMed ID: 26457546
[TBL] [Abstract][Full Text] [Related]
35. [Analysis of biological characteristics and prognosis on gastrointestinal stromal tumor with PDGFRA gene mutation].
Qi C; Pan F; Li J; Li Y; Gao J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1280-1284. PubMed ID: 30506540
[TBL] [Abstract][Full Text] [Related]
36. Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.
Ihle MA; Huss S; Jeske W; Hartmann W; Merkelbach-Bruse S; Schildhaus HU; Büttner R; Sihto H; Sundby Hall K; Eriksson M; Reichardt P; Joensuu H; Wardelmann E
PLoS One; 2018; 13(2):e0193048. PubMed ID: 29451912
[TBL] [Abstract][Full Text] [Related]
37. The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study.
Yang W; Liu Q; Lin G; Zhang B; Cao H; Zhao Y; Xia L; Feng F; Xiong Z; Hu J; Ye Y; Tao K; Zhang P
J Surg Oncol; 2021 Dec; 124(7):1128-1135. PubMed ID: 34324197
[TBL] [Abstract][Full Text] [Related]
38. Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study.
Qianyi W; Mei X; Rui Z; Yong W; Yutao W; Xiaoding S; Xiaoting W
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1493-1500. PubMed ID: 34319443
[TBL] [Abstract][Full Text] [Related]
39. Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.
Cavnar MJ; Wang L; Balachandran VP; Antonescu CR; Tap WD; Keohan M; Singer S; Temple L; Nash GM; Weiser MR; Guillem JG; Aguilar JG; DeMatteo RP; Paty PB
Ann Surg Oncol; 2017 Dec; 24(13):3972-3980. PubMed ID: 29058144
[TBL] [Abstract][Full Text] [Related]
40. [A multicentre retrospective cohort study of patients with gastrointestinal stromal tumors in Shandong Province].
Ning L; Yan W; Zhang M; Gong H; Dai Y; Jiang L; Lin H; Zhang D; Zhou Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr; 17(4):326-30. PubMed ID: 24760638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
